Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H16ClN5O2 |
| Molecular Weight | 381.816 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](OC1=NN=C(N1C)C2=CC=NC=C2)C3=NOC(=C3)C4=CC(Cl)=CC=C4
InChI
InChIKey=SXWHYTICXCLKDG-GFCCVEGCSA-N
InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1
| Molecular Formula | C19H16ClN5O2 |
| Molecular Weight | 381.816 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AstraZeneca was developing AZD-2066, a metabotropic glutamate receptor 5 (mGLUR5) antagonist, for the oral treatment of pain indications (e.g. chronic neuropathic pain and painful diabetic neuropathies), depressive disorders and gastro-oesophageal reflux disease. AZD-2066 had been in phase II clinical trials by AstraZeneca for the treatment of diabetic neuropathic pain and phase I for the treatment of gastrooesophageal reflux disease (GERD). However, this reasearch had being discontinued.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22469098 |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZD-2066 blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
Treatment of pain: capsule, once daily, 12 mg AZD-2066 day 1-4 and 18 mg AZD2066 day 5-28.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: AZD-2066 (0–300 uM, 0–100 uM for CYP2C9) and specific
probe substrates were pre-incubated with human liver
microsomes for 10 min before the reactions were initiated by
the addition of NADPH to give a final incubation volume of
100 uL.
In vitro inhibition by AZD-2066 was observed for the following CYP:
CYP1A2 (IC50=14.3 uM), CYP2B6 (IC50=7.4 uM), CYP2C9 (IC50=4.9 μM), CYP2C19 (IC50=9.6 μM) and
CYP2D6 (IC50=15 μM). Inhibition of CYP3A4 was also
observed, with 60 and 80 % of inhibition at the highest tested
concentration of AZD-2066 (300 uM) with midazolam and
testosterone as the probe substrates, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:50:29 UTC 2023
by
admin
on
Sat Dec 16 01:50:29 UTC 2023
|
| Record UNII |
MQ908Y1ZB2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3545164
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY | |||
|
934282-55-0
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY | |||
|
100000175777
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY | |||
|
DB12644
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY | |||
|
MQ908Y1ZB2
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY | |||
|
16041426
Created by
admin on Sat Dec 16 01:50:29 UTC 2023 , Edited by admin on Sat Dec 16 01:50:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
ANTAGONIST
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
